# Lipocine Inc. (LPCN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LPCN
## Company Profile
- Ticker: LPCN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.09 USD
- Market cap: 18549569.25 USD
- Last updated: 2026-08-11
## Business Overview
### Oral Drug-Delivery Platform
Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.
### LPCN 1154
LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future development path uncertain.
### Product-Focused Development Model
The company applies its formulation technology to established active pharmaceutical ingredients, seeking differentiated dosing, convenience or pharmacokinetic profiles in endocrine and neuropsychiatric indications.
## Why The Stock Is Moving

As of Aug 11, 2026, LPCN closed down 0.48% at $2.09. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-04 12:00 EST — [Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026](https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2026-2511d375) — Source: Lipocine Inc.
- 2026-08-03 12:00 EST — [Lipocine Appoints Michael J. Grissinger to Board of Directors](https://biopharmsignal.com/news/LPCN/lipocine-appoints-michael-j-grissinger-to-board-of-directors-28b9afc6) — Source: Lipocine Inc.
- 2026-06-04 12:00 EST — [Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154](https://biopharmsignal.com/news/LPCN/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-the-clinical-profile-of-lpcn-1154) — Source: Lipocine Inc.
- 2026-05-19 12:00 EST — [Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting](https://biopharmsignal.com/news/LPCN/lipocine-announces-lpcn-1154-phase-3-data-accepted-for-oral-presentation-at-2026-ascp-annual-meeting) — Source: Lipocine Inc.
- 2026-05-18 12:00 EST — [Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase](https://biopharmsignal.com/news/LPCN/lipocine-to-present-at-a-g-p-s-annual-virtual-healthcare-company-showcase) — Source: Lipocine Inc.